These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22196123)

  • 21. Design, synthesis and biological evaluation of β-carboline derivatives as novel inhibitors targeting B-Raf kinase.
    Xin B; Tang W; Wang Y; Lin G; Liu H; Jiao Y; Zhu Y; Yuan H; Chen Y; Lu T
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4783-6. PubMed ID: 22704238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
    Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
    Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of BRAF inhibitors through in silico screening.
    Luo C; Xie P; Marmorstein R
    J Med Chem; 2008 Oct; 51(19):6121-6127. PubMed ID: 18783202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
    Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
    Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY
    J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly enantioselective hydrosilylation of N-(1,2-diarylethylidene)arylamines.
    Zheng Y; Xue Z; Liu L; Shu C; Yuan W; Zhang X
    Org Biomol Chem; 2013 Jan; 11(3):412-5. PubMed ID: 23208651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual binding site inhibitors of B-RAF kinase.
    Wolin RL; Bembenek SD; Wei J; Crawford S; Lundeen K; Brunmark A; Karlsson L; Edwards JP; Blevitt JM
    Bioorg Med Chem Lett; 2008 May; 18(9):2825-9. PubMed ID: 18434146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
    Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
    Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
    Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.